DaRT Radiotherapy Source Balancing Radon Release and Beta Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing diffusing alpha-emitter radiation therapy (DaRT) methods face challenges in ensuring effective tumor cell destruction near the tumor perimeter due to reduced alpha radiation efficacy from dense membrane structures and high blood supply, leading to insufficient radiation coverage and potential healthy tissue damage from radon atoms.
Innovation Solution
Implementing radiotherapy sources that combine alpha and beta radiation by adjusting radon release rates and desorption probabilities, using a low desorption probability to increase beta radiation while maintaining effective alpha radiation, with coatings and heat treatments to control radionuclide release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the radon release rate is increased to improve tumor destruction, then the radiation dose to tumor cells increases, but the risk of damaging distant healthy tissue increases
Solution Approach 1:
The patent applies local quality by creating spatial differentiation in radiation type distribution. Alpha radiation is concentrated within the tumor volume to maximize local destruction, while beta radiation is directed preferentially toward the tumor periphery where hypoxic cells reside. This spatial differentiation of radiation qualities allows effective tumor treatment while minimizing damage to distant healthy tissues through the short range of both radiation types.
Solution Approach 2:
The patent utilizes parameter changes by exploiting the different physical properties of alpha and beta radiation. Alpha particles have high linear energy transfer (LET) and short range, while beta particles have lower LET but longer range. By adjusting the mixture and distribution of these radiation types from the seed, the patent optimizes the balance between tumor destruction and healthy tissue protection.
2Reliability
If alpha radiation is used to destroy tumor cells, then cell destruction effectiveness increases, but coverage near the tumor perimeter is insufficient due to dense membranes and high blood supply
Solution Approach 1:
The patent merges two types of radiation (alpha and beta) with complementary properties into a single therapeutic approach. Alpha radiation provides high-LET cell killing in the tumor core, while beta radiation extends coverage to the periphery where alpha particles cannot effectively penetrate due to dense membranes and rapid clearance by blood supply. This combination creates comprehensive tumor coverage from core to periphery.
Solution Approach 2:
The patent adds a dimensional aspect to radiation therapy by considering both the radial distance from the seed and the type of radiation. Alpha particles operate effectively at very short ranges (core region), while beta particles extend the therapeutic effect to larger distances (peripheral region). This dimensional stratification of radiation types overcomes the limitation of single-type radiation coverage.
3Reliability
If radium activity is increased to ensure sufficient radiation dose, then tumor destruction probability increases, but the amount of radon atoms released into blood increases causing healthy tissue damage
Solution Approach 1:
The patent converts what would normally be wasted radon atoms (those that escape into the blood) into a beneficial therapeutic agent. Beta-emitting radon atoms that enter the bloodstream are redirected to preferentially target hypoxic cells at the tumor periphery, transforming a potential harm (radon in blood) into a benefit (enhanced peripheral tumor cell destruction). This approach allows higher radium activity without proportionally increasing damage to healthy tissues.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances tumor cell destruction by increasing beta radiation without increasing systemic alpha radiation exposure, ensuring comprehensive tumor coverage and minimizing healthy tissue damage.
Implementation Method 1
radium-223 or radium-224 atoms, which generate chains of several radioactive decays
Implementation Method 2
These radionuclides, and their own radioactive daughter atoms, spread around the source by diffusion up to a radial distance of a few millimeters
Implementation Method 3
Alpha particles are a powerful means for radiotherapy since they induce clustered double-strand breaks on the DNA
Implementation Method 4
The beta radiation is much weaker than the alpha radiation, and has a longer range than the alpha radiation
Data Source
AI summary
A radiotherapy source includes a base and radioactive atoms of one or more isotopes, which are attached to the base. The radioactive atoms have a radon release rate of at least 0.5 micro-Curie (μCi) per centimeter length, and emit beta radiation achieving at 2 millimeters from the base an asymptotic dose of at least 10 Gy. Additionally, the ratio between the beta radiation asymptotic dose at a distance of 2 millimeters from the device to the radon release rate, is greater than 15 Gy/(microcurie/cm).